Test Price
2,800 AED✅ Home Collection Available
HOXA13 Gene Hand-Foot-Uterus Syndrome Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited NGS processing and clinical validation.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test clinical guidance for result interpretation by DHA-licensed specialists.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The HOXA13 gene NGS test screens for pathogenic variants causing Hand-Foot-Uterus Syndrome (HFU), a rare autosomal dominant dysmorphology disorder. Our advanced Next-Generation Sequencing identifies even low-frequency mosaic mutations, enabling definitive diagnosis and informed genetic counselling.
| Feature | Our Test (HOXA13 NGS – DHA Approved) | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Methodology | NGS (Next‑Generation Sequencing) – comprehensive coding region & splice sites | Sanger sequencing – limited to known hotspots |
| Variant Detection | SNVs, indels, copy number variants (CNVs) – full gene analysis | Only selected point mutations; miss large deletions/duplications |
| Turnaround Time | 3–4 Weeks (21–28 business days) | 5–6 Weeks |
| Sample Types | Whole Blood, Extracted DNA, Dried Blood Spot (FTA Card) – flexible home collection | Whole Blood only (venipuncture) |
| Diagnostic Sensitivity | >99.9% (validated against clinical datasets) | ~85–90% |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I understand the anxiety surrounding a potential diagnosis of Hand‑Foot‑Uterus Syndrome. The HOXA13 NGS test offers families a precise molecular answer, but it must always be interpreted in the full clinical context—including limb, urogenital, and family history. A negative result does not exclude other genetic syndromes, and a positive result opens the door to tailored management and reproductive options.”
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Pre-Test Advisory & Consent
Pre-Test Genetic Counseling & Consent
- All patients must receive pre-test genetic counselling to understand the implications of a positive, negative, or inconclusive result.
- Informed written consent is mandatory under UAE law; for minors, parental or guardian consent is required.
- Results are communicated by a DHA-licensed geneticist, ensuring appropriate medical follow-up.
Exclusion Criteria & Safety Precautions
Test Exclusion Criteria & Emergency Red Flags
- Exclusion from testing: Individuals without a documented clinical indication for HFU syndrome; patients unable to provide an adequate blood or DNA sample; non-consenting adults.
- Post-collection red flags: Prolonged bleeding at the puncture site, signs of infection (worsening redness, swelling, fever), or syncope – seek immediate emergency care.
- Critical reminder: This test is for diagnostic confirmation and does not replace a clinical exam. Never discontinue prescribed medications without consulting your physician.
Patient FAQ & Clinical Guidance
1. What exactly does the HOXA13 NGS test detect, and why is it needed?
Answer: The test analyzes the entire HOXA13 gene to identify disease‑causing mutations responsible for Hand‑Foot‑Uterus Syndrome, a rare genetic condition. It provides a definitive molecular diagnosis when clinical symptoms (small hands/feet, uterine anomalies) are present, guiding treatment and family planning.
2. How is the sample collected, and is home service available?
Answer: A certified phlebotomist collects blood (or a painless finger‑prick for an FTA card) at your home between 8 AM and 11 PM. The sample is transported in a temperature‑controlled cold chain to our ISO‑accredited lab, guaranteeing integrity without you needing to visit a clinic.
3. Are my genetic data confidential under UAE law?
Answer: Absolutely. Your genomic information is protected under the UAE Personal Data Protection Law (Federal Decree‑Law No. 45 of 2021) and Federal Law No. 2 of 2019, which prohibit any sharing of genetic results without your explicit consent. Only encrypted data is stored on secure servers.
UAE Regulatory & Data Privacy Adherence
This HOXA13 genetic test strictly adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted and processed with explicit consent. Our facility maintains ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and DHA Facility License 1143.
Clinical & Logistical Metadata
| Test Name | HOXA13 Gene Hand-Foot-Uterus Syndrome Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks (21–28 business days) |
| Sample Type / Matrix | Whole Blood, Extracted DNA, Dried Blood Spot (FTA Card) |
| Methodology Used | Next‑Generation Sequencing (NGS) – comprehensive coding region & splice site analysis |
| ICD-10-CM Code | Q87.2 (Congenital malformation syndromes predominantly involving limbs) |
| LOINC Code | 83134-7 (HOXA13 gene targeted mutation analysis) |
| DHA Facility License & Laboratory Address | DHA License: 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians